Sprint Bioscience Q4 2022: Temporary setbacks
Research Update
2023-02-16
06:45
Redeye comments on Sprint Bioscience’s Q4 2022 report, and we judge that the company is closing in on a licensing deal for its VADA project H1 2023e after some setbacks in recent months. We tweak our estimates and valuation.
CB
EL
Christian Binder
Ethel Luvall
Disclosures and disclaimers